Singapore, March 20 -- based biopharmaceutical company focused on the discovery, development, manufacturing and commercialisation of innovative medicines and vaccines, has announced that the Singapore Health Sciences Authority (HSA) has approved NEFEGAN for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression.

NEFEGAN, known in other Everest territories as Nefecon, was the first ever treatment for IgAN fully approved by the US Food and Drug Administration, and Singapore marks the third region in Everest territories that received New Drug Application (NDA) approval after Macao and mainland China.

Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with p...